Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects - PubMed (original) (raw)
Clinical Trial
. 2011 Nov;104(11):957-70.
doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.
D E Reece, V Sanchorawala, U Hegenbart, G Merlini, G Palladini, J-P Fermand, R A Vescio, J Bladé, L T Heffner, H Hassoun, X Liu, C Enny, P Ramaswami, Y Elsayed, H Van De Velde, S Mortimer, A Cakana, R L Comenzo; Velcade Can2007 Study Group
Affiliations
- PMID: 21752867
- DOI: 10.1093/qjmed/hcr105
Clinical Trial
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
S W Dubrey et al. QJM. 2011 Nov.
Abstract
Background: Bortezomib is approved for the treatment of multiple myeloma and a role has been suggested in the treatment of systemic AL amyloidosis (AL).
Methods: In this phase 1 dose-escalation portion of the first prospective study of single-agent bortezomib in AL, 31 patients with relapsed disease, including 14 (45%) with cardiac involvement, received bortezomib in seven dose cohorts on once-weekly (0.7, 1.0, 1.3, 1.6 mg/m(2)) and twice-weekly (0.7, 1.0, 1.3 mg/m(2)) schedules. Electrocardiographic, Holter and echocardiographic studies were evaluated in all patients to determine safety and response.
Results: During therapy (median treatment period 210 days), no patient developed significant ventricular or supraventricular rhythm disturbance on 24-h Holter monitoring; however, no patient satisfied study criteria for cardiac response using echocardiographic assessment or New York Heart Association classification. Seven patients (23%) had a ≥ 10% fall in left ventricular ejection fraction, but only one met criteria for cardiac deterioration. The predominant cardiac adverse events were peripheral edema (23%), orthostatic hypotension (13%) and hypotension (10%). Two patients developed grade 3 congestive heart failure, which resolved following treatment interruption. In this Phase 1 portion, the maximum tolerated dose of bortezomib on either schedule was not reached. Hematologic responses occurred in 14 patients (45%), including seven (23%) complete responses. In non-responders mean left ventricular wall thickness increased during the course of treatment.
Conclusion: AL is frequently rapidly progressive; in these patients who had relapsed or progressed following previous conventional therapies, these results suggest that bortezomib may slow the progression of cardiac amyloid with limited toxicity.
Similar articles
- Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Fukushima T, et al. Anticancer Res. 2011 Jun;31(6):2297-302. Anticancer Res. 2011. PMID: 21737655 - Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Reece DE, et al. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. Blood. 2009. PMID: 19498019 Clinical Trial. - Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Ghobrial IM, et al. Lancet Oncol. 2011 Mar;12(3):263-72. doi: 10.1016/S1470-2045(11)70028-6. Epub 2011 Feb 21. Lancet Oncol. 2011. PMID: 21345726 Clinical Trial. - Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Badros A, et al. Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921. Cancer. 2007. PMID: 17654660 Review. - Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Bockorny M, et al. Acta Haematol. 2012;128(4):244-7. doi: 10.1159/000340050. Epub 2012 Sep 4. Acta Haematol. 2012. PMID: 22964848 Review.
Cited by
- Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies.
Jattin-Balcázar JJ, Quiroga-Ramírez PA. Jattin-Balcázar JJ, et al. Curr Drug Saf. 2024;19(4):444-454. doi: 10.2174/0115748863264472231227060926. Curr Drug Saf. 2024. PMID: 38204273 - The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis.
Jiang F, Chen J, Liu H, Li L, Lu W, Fu R. Jiang F, et al. Indian J Hematol Blood Transfus. 2018 Apr;34(2):216-226. doi: 10.1007/s12288-018-0937-x. Epub 2018 Mar 7. Indian J Hematol Blood Transfus. 2018. PMID: 29622862 Free PMC article. - A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. Laubach JP, et al. Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466536 Free PMC article. - Newer Therapies for Amyloid Cardiomyopathy.
Chakraborty R, Muchtar E, Gertz MA. Chakraborty R, et al. Curr Heart Fail Rep. 2016 Oct;13(5):237-246. doi: 10.1007/s11897-016-0300-1. Curr Heart Fail Rep. 2016. PMID: 27497715 Review. - Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.
Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y. Shimazaki C, et al. Int J Hematol. 2016 Jan;103(1):79-85. doi: 10.1007/s12185-015-1901-2. Epub 2015 Nov 20. Int J Hematol. 2016. PMID: 26588925 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous